NCT07096453View on ClinicalTrials.gov

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Kidney Transplant; ComplicationsCMV
Interventions
DRUG

Cytogam

Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT07096453 - CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter